- Home
- LZ vs PRAX Comparison
LZ vs PRAX Comparison
Compare LZ & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- PRAX
- Stock Information
- Founded
- LZ 2001
- PRAX 2015
- Country
- LZ United States
- PRAX United States
- Employees
- LZ N/A
- PRAX N/A
- Industry
- LZ EDP Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- LZ Technology
- PRAX Health Care
- Exchange
- LZ Nasdaq
- PRAX Nasdaq
- Market Cap
- LZ 1.6B
- PRAX 1.4B
- IPO Year
- LZ 2021
- PRAX 2020
- Fundamental
- Price
- LZ $8.67
- PRAX $74.49
- Analyst Decision
- LZ Hold
- PRAX Strong Buy
- Analyst Count
- LZ 10
- PRAX 9
- Target Price
- LZ $8.36
- PRAX $149.00
- AVG Volume (30 Days)
- LZ 1.9M
- PRAX 388.8K
- Earning Date
- LZ 02-26-2025
- PRAX 03-04-2025
- Dividend Yield
- LZ N/A
- PRAX N/A
- EPS Growth
- LZ 212.91
- PRAX N/A
- EPS
- LZ 0.13
- PRAX N/A
- Revenue
- LZ $678,838,000.00
- PRAX $1,605,000.00
- Revenue This Year
- LZ $6.16
- PRAX N/A
- Revenue Next Year
- LZ $2.22
- PRAX N/A
- P/E Ratio
- LZ $66.41
- PRAX N/A
- Revenue Growth
- LZ 4.65
- PRAX N/A
- 52 Week Low
- LZ $5.33
- PRAX $33.01
- 52 Week High
- LZ $13.74
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- LZ 46.06
- PRAX 42.80
- Support Level
- LZ $8.82
- PRAX $76.00
- Resistance Level
- LZ $9.30
- PRAX $91.83
- Average True Range (ATR)
- LZ 0.28
- PRAX 6.29
- MACD
- LZ -0.08
- PRAX -1.10
- Stochastic Oscillator
- LZ 12.26
- PRAX 2.42
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.